Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Elanco Animal Health turns veterinary science into revenue isn’t easy—each 10-K details dozens of R&D pipeline assets, FDA approvals, and integration costs from the Bayer Animal Health acquisition. If you have ever asked, “Where can I read Elanco’s quarterly earnings report 10-Q filing?” or “How do I locate Elanco insider trading Form 4 transactions?” you already know the challenge.
Stock Titan solves it. Our AI-powered summaries translate the technical language in every Elanco SEC document into plain English, flagging segment margins, companion-animal growth, and farm-animal productivity trends. Receive real-time alerts the moment an Elanco Form 4 insider transactions real-time filing hits EDGAR, or open an Elanco 8-K material events explained card to see if a new parasiticide received FDA approval—all without wading through hundreds of pages.
Here’s what you can explore in seconds:
- Elanco annual report 10-K simplified—AI highlights pipeline updates, manufacturing efficiencies, and acquisition synergies.
- Elanco quarterly earnings report 10-Q filing—compare sequential companion-animal sales and R&D spend.
- Elanco proxy statement executive compensation—see how leadership incentives align with product launch milestones.
- Elanco executive stock transactions Form 4—monitor insider buying ahead of material announcements.
Whether you search “understanding Elanco SEC documents with AI” or need fast Elanco earnings report filing analysis, our platform keeps every filing type in one place, updated the moment Elanco submits it. Save hours, spot trends early, and make better calls on ELAN.
Elanco Animal Health Inc.'s President, CEO and Director Jeffrey N. Simmons acquired 166.1212 deferred stock units on 08/08/2025 under the company's Executive Deferral and Stock Match Plan. Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent. After the reported acquisition, Mr. Simmons beneficially owns 17,387.0337 common stock-equivalent units on a direct basis. The deferred units may settle in cash or shares following termination of employment or during a specified future year.
This Form 4, filed for Elanco Animal Health Inc. (ELAN), reports that Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation, had a transaction dated 08/08/2025. The filing shows acquisition of deferred stock units with a recorded amount of 6,735.3051 (displayed in the form) and a price field showing $16.67. The form notes each deferred stock unit represents the right to receive one share of common stock or the cash equivalent and that units settle in cash or shares following termination of employment or during a specified future year under the Executive Deferral and Stock Match Plan. The filing was signed by Amy C. Seidel as attorney-in-fact on 08/12/2025 and was filed by one reporting person.
Elanco Animal Health (ELAN) reported a proposed sale of 49,333 shares of common stock through UBS on the NYSE with an aggregate market value of $830,000, representing approximately 0.01% of the 496,646,504 shares outstanding. The filing lists the acquisition history: 1,536 shares on 12/03/2020, 16,738 shares on 02/22/2021, and 31,059 shares on 02/22/2022, all identified as stock awards.
The notice indicates no securities sold in the past three months and includes the signatory's representation that they do not know any material nonpublic information about the issuer. The form references Rule 144 procedures and mentions Rule 10b5-1 plan disclosure but does not provide a plan adoption or instruction date.
Elanco (ELAN) Q2 2025 10-Q highlights:
- Revenue rose 4.8% YoY to $1.24 bn; pet-health up 11% to $643 m, offsetting the divested aqua unit (zero vs $49 m).
- Gross margin held at 57.4% (713 m/1,241 m).
- Operating profile: SG&A climbed 13% to $400 m; R&D up 3% to $92 m; special charges plunged to $1 m from $80 m, driving a swing to positive pretax income of $25 m (-$32 m LY).
- Net income $11 m vs -$50 m; diluted EPS $0.02 vs -$0.10.
- Six-month totals: revenue +1.9% to $2.43 bn; net income $78 m vs -$18 m.
- Cash flow: operating cash +15% to $233 m; FCF negative as capex doubled to $122 m (new HQ).
- Balance sheet: cash $539 m (+$71 m YTD); total debt trimmed to $3.95 bn (ex-lease) from $4.32 bn; however a new $255 m finance lease and $293 m liability tied to royalty sale raise fixed commitments.
- Inventory up 6% YoY to $1.67 bn; accounts receivable +23%.
- Leverage: ~4.1× EBITDA remains high but 89% of debt is fixed; interest expense down 26% YoY.
- Strategic moves: • Closed $295 m royalty monetization with Blackstone (16.1% implied IRR). • HQ lease in Indianapolis (option to buy at $250 m in 2030). • Continued rollout of Zenrelia, Credelio Quattro, Bovaer; EU Zenrelia approval in Jul-25.
- Guidance not updated in filing.
Key takeaways: Return to profitability aided by lower one-offs and interest expense; pet-health momentum strong. Balance-sheet de-risking continues, but inventory build, rising SG&A and new fixed obligations temper the improvement.
FAQ
What is the current stock price of Elanco Animal Health (ELAN)?
What is the market cap of Elanco Animal Health (ELAN)?
